Influence of concurrent capecitabine based chemoradiotherapy with bevacizumab on the survival rate, late toxicity and health-related quality of life in locally advanced rectal cancer: a prospective phase II CRAB trial

Velenik, Vaneja; Zadnik, Vesna; Omejc, Mirko; Grosek, Jan; Tuta, Mojca

doi:10.2478/raon-2020-0043

Cited by 6 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mechanisms underlying the effects of radiation on sexual function include nerve and vascular damage, as well as fibrosis [29]. Radiotherapy reportedly adversely affects erectile capacity and retention, with the adverse effects being greatest at 8 months postoperatively, after which recovery is reportedly slow and incomplete [30,31]. RALS, the latest advancement in minimally invasive surgery, provides several advantages over CLS [32].…”

Section: Discussion and Con Clus Ionsmentioning

confidence: 99%

Risk factors for and longitudinal course of male sexual dysfunction after robotic rectal cancer surgery

et al. 2023

View full text Add to dashboard Cite

Aim The aim of this work was to investigate the risk factors associated with the incidence of sexual dysfunction in patients who underwent robot‐assisted surgery with several treatment options, such as neoadjuvant chemoradiotherapy and lateral lymph node dissection, and clarify the longitudinal course of erectile function in risk groups. Method A total of 203 male patients who underwent robot‐assisted total mesorectal excision for rectal cancer between 2013 and 2019 were included. The risk factors for erectile and ejaculatory dysfunction as well as the longitudinal course of erectile function were retrospectively investigated in all cohorts and several risk groups, including those who underwent neoadjuvant chemoradiotherapy, lateral lymph node dissection and adjuvant chemotherapy. Erectile dysfunction was assessed using the International Index of Erectile Function and ejaculatory dysfunction was assessed using original questions. The survey was performed preoperatively and at 3, 6 and 12 months postoperatively. Results Erectile and ejaculatory dysfunction occurred in 46.8% and 15.7% of the patients, respectively. Multivariate analysis showed that neoadjuvant chemoradiotherapy was an independent risk factor for erectile dysfunction. Erectile function recovered longitudinally to the preoperative level overall, as well as in lateral lymph node dissection and postoperative adjuvant chemotherapy subgroups; however, recovery was poor in the neoadjuvant chemoradiotherapy group, even at 12 months postoperatively. Conclusion Neoadjuvant chemoradiotherapy was found to be a risk factor for erectile dysfunction after robot‐assisted surgery for rectal cancer. Erectile function recovered postoperatively in patients undergoing lateral lymph node dissection; however, those receiving neoadjuvant chemoradiotherapy showed poor recovery, even at 12 months postoperatively.

show abstract

Section: Discussion and Con Clus Ionsmentioning

confidence: 99%

Risk factors for and longitudinal course of male sexual dysfunction after robotic rectal cancer surgery

et al. 2023

View full text Add to dashboard Cite

show abstract

“…According to Velenik et al [ 24 ], radiotherapy combined with capecitabine in patients after neoadjuvant treatment of rectal cancer can improve the survival rate. In this study, it was found that the progression-free survival and 2-year survival rate in the experimental group were significantly better than those in the control group, with statistical significance ( P < 0.05), which indicated that radiotherapy combined with capecitabine can promote tumor regression, thereby improving patients' postoperative survival.…”

Section: Discussionmentioning

confidence: 99%

Clinical Effect of Radiotherapy Combined with Capecitabine after Neoadjuvant Therapy for Rectal Cancer

Zhang

Teng

2021

Journal of Oncology

View full text Add to dashboard Cite

Objective. The purpose of the study was to investigate the clinical effect of radiotherapy combined with capecitabine in rectal cancer patients after neoadjuvant therapy. Methods. 80 rectal cancer patients who underwent neoadjuvant therapy in our hospital from February 2016 to February 2018 were selected as the study subjects and divided into the control group (n = 40) and experimental group (n = 40) according to the order of admission. Among them, the control group was treated with radiotherapy, while the experimental group was treated with radiotherapy combined with capecitabine. The therapeutic efficacy, CEA levels, the incidence and recurrence rate of adverse reactions, as well as the progression-free survival and survival rate after 2-year treatment were analyzed in the two groups. Results. The effective rate of treatment in the experimental group of 87.5% (35/40) was significantly higher than 50% (20/40) in the control group, with statistical significance (X2 = 13.09, P < 0.001 ). After treatment, the CEA levels in the two groups both decreased significantly, and the CEA level in the experimental group of 3.75 ± 1.76 ng/ml was significantly lower than 7.35 ± 2.11 ng/ml in the control group, with statistical significance (T = 8.29, P < 0.001 ). The incidence and the recurrence rate of adverse reactions of 5% (2/40) and 10% (4/40), respectively, in the experimental group were significantly lower than those of 40% (16/40) and 30% (12/40) in the control group, with statistical significance (X2 = 14.05, 5.00, P < 0.001 , 0.05). After the 2-year follow-up, it was found that the progression-free survival of 21.53 ± 6.23 months in the experimental group was significantly longer than that of 18.18 ± 5.41 months in the control group, with statistical significance (T = 2.57, P < 0.05 ), and the 2-year survival rate of 97.5% (39/40) in the experimental group was significantly higher than 80% (32/40) in the control group, with statistical significance (T = 6.13, P < 0.05 ). Conclusion. Radiotherapy combined with capecitabine in rectal cancer patients after neoadjuvant therapy can improve the therapeutic efficacy with fewer adverse reactions and longer patients’ survival, which is worthy of popularization and application after neoadjuvant therapy for rectal cancer.

show abstract

“…A previous study showed that six cycles of bevacizumab in combination with chemotherapy, followed by chemoradiotherapy (CRT) achieved an objective response rate (ORR) of 88.9% in locally advanced colorectal patients with T4 or high-risk T3, with R0 resection rate of 97.8% (Masi et al, 2019). Similarly, the CRAB study reported a 95% R0 resection rate in patients with stage II/III rectal cancer treated with neoadjuvant bevacizumab + CRT (Velenik et al, 2020). Although these studies reported positive outcomes, available evidence is insufficient to support the adoption of bevacizumab as a standard neoadjuvant (Table 1).…”

Section: Neoadjuvant Therapymentioning

confidence: 97%

Progress of research on molecular targeted therapies for colorectal cancer

Huang

Gao

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common malignancies, accounting for approximately 10% of global cancer incidence and mortality. Approximately 20% of patients with CRC present metastatic disease (mCRC) at the time of diagnosis. Moreover, up to 50% of patients with localized disease eventually metastasize. mCRC encompasses a complex cascade of reactions involving multiple factors and processes, leading to a diverse array of molecular mechanisms. Improved comprehension of the pathways underlying cancer cell development and proliferation, coupled with the accessibility of relevant targeted agents, has propelled advancements in CRC treatment, ultimately leading to enhanced survival rates. Mutations in various pathways and location of the primary tumor in CRC influences the efficacy of targeted agents. This review summarizes available targeted agents for different CRC pathways, with a focus on recent advances in anti-angiogenic and anti-epidermal growth factor receptor agents, BRAF mutations, and human epidermal growth factor receptor 2-associated targeted agents.

show abstract

Influence of concurrent capecitabine based chemoradiotherapy with bevacizumab on the survival rate, late toxicity and health-related quality of life in locally advanced rectal cancer: a prospective phase II CRAB trial

Cited by 6 publications

References 40 publications

Risk factors for and longitudinal course of male sexual dysfunction after robotic rectal cancer surgery

Risk factors for and longitudinal course of male sexual dysfunction after robotic rectal cancer surgery

Clinical Effect of Radiotherapy Combined with Capecitabine after Neoadjuvant Therapy for Rectal Cancer

Progress of research on molecular targeted therapies for colorectal cancer

Contact Info

Product

Resources

About